Valerie Lee
Medical Oncology · Baltimore, MDNPI 1821389701
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,650 of the $10,226 with a category attached, or 84.6%. Incyte Corporation accounts for 72.0% of it on its own, with 3 other manufacturers making up the rest.
Across 14 payments — averaging $730.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$7K
- Sirtex Medical Inc$3K
- Takeda Pharmaceuticals U.S.A., Inc.$125
- Medline Industries LP$27
Across 32 payments — averaging $26,370 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$687K
- Novartis$108K
- Corcept Therapeutics$49K
What the payments were for
- Consulting fees$8,65085%
- Travel & lodging$1,08311%
- Food & beverage$4935%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 10 | $7,365 |
| Sirtex Medical Inc | 2 | $2,710 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $125 |
| Medline Industries LP | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZYNYZ$3,385
- SIR-Spheres Microspheres$2,710
- FRUZAQLA$125
How this compares
$10,226 in reported general payments places this provider in the 60th percentile of 180 medical oncology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LynparzaOlaparib | 13 | $191,608 |
| CreonLipase/Protease/Amylase | 39 | $93,294 |
| EliquisApixaban | 25 | $24,850 |
| XareltoRivaroxaban | 11 | $11,505 |
| Prochlorperazine Maleate | 44 | $718 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 20 | $702 |
| Dexamethasone | 16 | $417 |
| Ondansetron Hcl | 29 | $415 |
| Morphine Sulfate | 12 | $407 |
| Duloxetine Hcl | 17 | $285 |
| Levothyroxine Sodium | 14 | $244 |
| Oxycodone Hcl | 15 | $171 |
| Pantoprazole Sodium | 14 | $165 |
| Gabapentin | 12 | $118 |
| Amlodipine Besylate | 13 | $90 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Baltimore
- Mario EisenbergerBaltimore$2.9M
- David SidranskyBaltimore$520K
- Carole MillerBaltimore$331K
- Mark LevisBaltimore$323K
- Tanguy Lim-SeiwertBaltimore$301K
- Shruti ChaturvediBaltimore$265K
- Sandy KotiahBaltimore$247K
- Bruce SmithBaltimore$235K
- Evan LipsonBaltimore$228K
- Nilofer AzadBaltimore$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.